- BIA 10-2474
-
- $34.00 / 10mg
-
2025-10-20
- CAS:1233855-46-3
- Min. Order:
- Purity: 99.27%
- Supply Ability: 10g
- BIA10-2474
-
- $1.00 / 1g
-
2019-12-24
- CAS:1233855-46-3
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 20kg
|
| BIA10-2474 Basic information |
Product Name: | BIA10-2474 | Synonyms: | BIA10-2474;1H-Imidazole-1-carboxamide,N-cyclohexyl-N-methyl-4-(1-oxido-3-pyridinyl)-;CS-2451;BIA10-2474; BIA-10-2474;3-(1-(Cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide;BIA 10 2474,Fatty acid amide hydrolase,FAAH,Autophagy,Inhibitor,BIA 102474,BIA 10-2474,inhibit;BIA 10-2474 ,S5932 | CAS: | 1233855-46-3 | MF: | C16H20N4O2 | MW: | 300.36 | EINECS: | | Product Categories: | API | Mol File: | 1233855-46-3.mol |  |
| BIA10-2474 Chemical Properties |
storage temp. | Store at -20°C | solubility | DMSO:2.2(Max Conc. mg/mL);7.32(Max Conc. mM) | form | A crystalline solid | color | White to off-white |
| BIA10-2474 Usage And Synthesis |
Uses | N-Cyclohexyl-N-methyl-4-(1-oxido-3-pyridinyl)-1H-imidazole-1-carboxamide is a potential fatty acid amide hydrolase (FAAH) inhibitor used for treating and preventing diseases. | Synthesis | In a further step of this synthesis, N-cyclohexyl-N-methyl-4-(pyridin-3-yl)-1H-imidazole-1-carboxamide (90 g, 317 mmol) was dissolved in dichloromethane (1350 ml) in a 2L reactor followed by addition of peracetic acid (84 ml, 475 mmol). The reaction mixture was stirred at 25 °C and the progress of the reaction was monitored by HPLC until N-cyclohexyl-N-methyl-4-(pyridin-3-yl)-1H-imidazole-1-carboxamide was completely consumed. After completion of the reaction, an aqueous solution (270 ml) of sodium metabisulfite (60.2 g, 317 mmol) was slowly added, keeping the reaction temperature below 30 °C. After performing phase separation, the organic phase was washed with water. After phase separation again, the organic phase was concentrated to 1/5 of the original volume at atmospheric pressure.Subsequently, the solvent was replaced with isopropanol (1350 ml) and the suspension was cooled down to 0 °C over a period of 4 hours and stirring was continued at this temperature for 1 hour. The resulting white crystalline solid was collected by filtration and washed sequentially with water (270 ml) and isopropanol (270 ml) to give 84.8 g (89% yield) of the target product. | in vivo | In January 2016, severe adverse events (SAE) occurs in the Phase I clinical trial using the drug BIA 10-2474 including one death. The possibilities for failure of trials such as off-target effect, dose calculation, unexpected immune response, species variation, and cumulative dose toxicity would be sought[2]. | References | [1] Patent: WO2012/15324, 2012, A1. Location in patent: Page/Page column 58-59 [2] Patent: US2012/65191, 2012, A1. Location in patent: Page/Page column 32 [3] Patent: WO2014/17938, 2014, A2. Location in patent: Page/Page column 67; 68 |
| BIA10-2474 Preparation Products And Raw materials |
|